Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM

Torrent Pharmaceuticals — Q3 FY2013 Earnings Presentation

18 slides from Torrent Pharmaceuticals's earnings presentation, 2013

  1. Slide 1: Investor Presentation Q3 FY 2013

    TORRENT PHARMACEUTICALS LTD. Investor Presentation Q3 FY 2013

  2. Slide 2: Caveat

    Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre

  3. Slide 3: Contents

    Contents 1. Performance Highlights 2. Financials 3. Business Segments – India – International 4. Facilities – Expansion Plan

  4. Slide 4: Q3 FY13 Highlights

    Q3 FY13 Highlights • Revenues at ` 798 Cr vs. ` 695 Cr, growing at 15% • Domestic revenue growth of 13% • International operations growing at 17% • US & ROW markets key contributors to growth of international operations • Brazil revenue degrowth of 3% on account of: • Currency movements; adjusting f

  5. Slide 5: Financials

    Financials

  6. Slide 6: Revenue Progression

    Revenue Progression ` Cr Particulars Q3 Q3 YTD YTD 11-12 10-11 12 - 13 11 - 12 12 - 13 11 - 12 India 258 229 807 711 909 834 Gwth % 13% 14% 9% International 449 393 1,306 1,092 1,478 1,122 Gwth % 14% 20% 32% Brazil 117 120 368 352 477 355 Europe (incl Heumann) 156 144 440 410 542 449 USA 92 64 263 1

  7. Slide 7: P&L

    P&L ` Cr Q3 Q3 YTD YTD Particulars 1 1 -1 2 1 0 -1 1 12 - 13 11 - 12 12 - 13 11 - 12 R e v e nue s 798 695 2,342 2,022 2,696 2,198 C ogs 247 222 684 640 863 697 % Re v e nue s 31% 32% 29% 32% 32% 32% SG&A Spend 247 199 695 558 778 673 % Re v e nue s 31% 29% 30% 28% 29% 31% Em ployee C os t 154 134 4

  8. Slide 8: Balance Sheet

    Balance Sheet ` Cr Particulars 31-Mar-12 % 31-Dec-12 % ∆ EQUITY AND LIABILITIES Shareholders' Funds 1,194 70% 1,529 74% 335 Minority Interest 4 0% 0 0% (3) Non-current liabilities 513 30% 543 26% 30 TOTAL 1,711 100% 2,072 100% 362 ASSETS Net Fixed Assets 916 54% 1,059 51% 143 Investments 124 7% 89 4

  9. Slide 9: Business Segments: India

    Business Segments India

  10. Slide 10: India: Highlights & Growth Drivers

    India Highlights & Growth Drivers ` Cr Q3 Q3 YTD YTD India 11 - 12 10 - 11 12 - 13 11 - 12 12 - 13 11 - 12 Revenues 258 229 807 711 909 834 %Growth 13% 14% 9% • Q3 FY 13 Highlights • MAT Nov 12 ~ IPM growth 12%; Covered market growth 15%; Torrent growth; 14%. • Acute therapy gwth (IPM: 11%;CM: 16%;

  11. Slide 11: Business Segments: International Operations

    Business Segments International Operations

  12. Slide 12: Brazil: Highlights & Growth Drivers

    Brazil Highlights & Growth Drivers ` Cr Q3 Q3 YTD YTD Brazil 11-12 10-11 12 - 13 11 - 12 12 - 13 11 - 12 Revenues 117 120 368 352 477 355 %Growth -3% 5% 34% • Q3 FY 13 Highlights • Reai growth 4%; volume growth 3%; New Introductions 1%. • IMS QTR (Sep- Nov) ; Torrent growing at 7% vs. Covered Market

  13. Slide 13: USA: Highlights & Growth Drivers

    USA Highlights & Growth Drivers ` Cr Q3 Q3 YTD YTD USA 11-12 10-11 12 - 13 11 - 12 12 - 13 11 - 12 Revenues 92 64 263 159 216 114 % Growth 44% 65% 89% • Q3 FY 13 Highlights • Revenue growth of 35% on constant currency basis • 2 ANDAs approved & 1 ANDA filled during the quarter. • 41 ANDAs & 24 DMFs

  14. Slide 14: Europe inc Heumann: Highlights & Growth Drivers

    Europe inc Heumann Highlights & Growth Drivers ` Cr Europe+ Q3 Q3 YTD YTD 11-12 10-11 Heumann 12- 13 11- 12 12- 13 11- 12 Revenues 156 144 440 410 542 449 %Growth 8% 7% 16% • Q3 FY 13 Highlights • Euro sales growth of 6% • UK & Romania progressing as per expectations • Growth Drivers • Heumann succe

  15. Slide 15: ROW inc RCIS: Highlights & Growth Drivers

    ROW inc RCIS Highlights & Growth Drivers ` Cr Q3 Q3 YTD YTD ROW+RCIS 11-12 10-11 12-13 11-12 12-13 11-12 Revenues 78 60 217 160 227 197 %Growth 30% 36% 16% • Q3 FY13 Highlights • Revenue growth of 22% on constant currency basis. • Growth Drivers • Middle East/ Africa Region Delivering the growth bei

  16. Slide 16: Facilities – Expansion Plan

    Facilities – Expansion Plan

  17. Slide 17: Facilities – Expansion Plan: Dahej SEZ

    Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1000 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 600 crores, First Regulatory Approval: Q1’14-15 • Pha

  18. Slide 18: Thank You

    Thank You

Torrent Pharmaceuticals — Q3 FY2013 Earnings Presentation on 6ix